Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG102-031 in Neovascular Age-related Macular Degeneration
NCT05903794Phase 1Completed
- Sponsor
- Exegenesis Bio
- Start
- Jul 2023
- Primary completion
- Feb 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EXG102 in neovascular age-related macular degeneration (NVAMD), sponsored by Exegenesis Bio. Primary endpoint: Evaluation of safety and tolerability at 52 weeks. Started Jul 2023; status: completed.
02
Drugs
EXG102
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05903794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903794.